Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daxxify for Benign Essential Blepharospasm and Hemifacial Spasm
NCT06195241Phase 4Recruiting
- Sponsor
- Montefiore Medical Center
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of botulinum toxin type A in benign essential blepharospasm (BEB), hemifacial spasm (HFS), sponsored by Montefiore Medical Center. Started Feb 2025; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
benign essential blepharospasm (BEB)hemifacial spasm (HFS)
Beyond the preview
Go deeper on NCT06195241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195241.